Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

Journal of Clinical Oncology

Volumn 19, Issue 6, 2001, Pages 1759-1767

  Campos, D ^a   Pereira, J R ^a   Reinhardt, R R ^a   Carracedo, C ^a   Poli, S ^a   Vogel, C ^a   Martinez Cedillo, J ^a   Erazo, A ^a   Wittreich, J ^a   Eriksson, L O ^a   Carides, A D ^a   Gertz, B J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; APREPITANT; CISPLATIN; DEXAMETHASONE; GRANISETRON; NEUROKININ 1 RECEPTOR ANTAGONIST; PLACEBO; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0035868769     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.6.1759     Document Type: Article

References (37)

1. Quality of life studies in chemotherapy-induced emesis
2. On the receiving end: V. Patient perceptions of the side effects of cancer chemotherapy
3. Emesis as a critical problem in chemotherapy
4. Controlling emesis in patients receiving cancer chemotherapy
5. The management of chemotherapy-induced nausea and vomiting
6. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin
7. Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: Comparison of placebo vs. adrenocorticotropic hormone (ACTH)
8. Delayed emesis following high-dose cisplatin: A double-blind randomized comparative trial of ondansetron (GR 38032F) versus placebo
9. Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin
10. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin
11. Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo
12. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study
13. Phase II trials of ondansetron with high-dose cisplatin
14. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicenter double-blind, randomized, parallel-group study
15. Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone
16. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy
17. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis
18. Ondansetron in the prophylaxis of acute and delayed cisplatin-induced emesis
19. Management of cisplatin-induced delayed emesis
20. Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin
21. Cisplatin and emesis: Aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin
22. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of Perugia Consensus Conference
23. Neuropharmacology of chemotherapy induced emesis
24. Anti-emetic activity of neurokinin NK1 receptor antagonists is mediated centrally in the ferret
25. Neurotransmitter functions of mammalian tachykinins
26. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets
27. 1 receptor, and potent broad-spectrum anti-emetic activity
28. 1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret
29. 1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
30. 1 receptor antagonist to prevent delayed emesis after cisplatin
31. Comparison of a neurokinin-1 antagonist L-758,298 to ondansetron in the prevention of cisplatin-induced emesis
32. Reduction of cisplatin-induced emesis by a selective neurokinin- 1 receptor antagonist
33. Proposal for classifying the acute emetogenicity of cancer chemotherapy
34. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting
35. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis